MTOR and breast carcinoma: In order to provide additional evidence of the inhibitory effects of formononetin on breast cancer proliferation through its impact on mTORC1 activity, we conducted a co-administration study using Formononetin and the mTOR inhibitor Torin-1 on MDA-MB-231 and MDA-MB-468 cells.